UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private
Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of March 2026
Commission file number: 001-42375
Polyrizon Ltd.
(Translation of registrant’s name into English)
5 Ha-Tidhar Street
Raanana, 4366507, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
Attached hereto and incorporated herein is the
Registrant’s press release issued on March 10, 2026, titled “Polyrizon Announces GMP Manufacturing of Clinical Trial Material
(CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study.”
The first five paragraphs of the press release attached to this Report
of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements
on Form S-8 (File No. 333-284410 and 333-288923)
and Form F-3 (333-291368),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study” |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Polyrizon Ltd. |
| |
|
| Date: March 10, 2026 |
By: |
/s/ Tomer Izraeli |
| |
Name: |
Tomer Izraeli |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Polyrizon
Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE)
-- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing
intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical
trial material (CTM) for its lead product candidate.
This milestone follows the Company’s
previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S, a leading global GMP CDMO, established to support
the supply of clinical trial material for Polyrizon’s clinical development program.
The GMP manufacturing milestone represents
a key step in Polyrizon’s clinical development program and supports the company’s preparations for a planned clinical study
in the United States later this year.
The GMP batch was manufactured following the
successful production of two prior development batches, which demonstrated batch-to-batch consistency and product stability over time,
supporting the robustness and reproducibility of the manufacturing process.
The CTM batch was produced in compliance with
applicable GMP standards in collaboration with Eurofins CDMO AmatsiAquitaine S.A.S, and will be used to support upcoming clinical activities
and regulatory submissions related to the study.
“This manufacturing milestone represents
an important step in advancing our clinical development strategy,” said Tomer Izraeli, CEO of Polyrizon. “Following the successful
production of development batches that confirmed manufacturing consistency and stability, the GMP production of clinical material enables
us to move forward with our planned U.S. clinical study and reflects our continued commitment to developing innovative intranasal solutions
designed to protect against airborne allergens and viruses.”
This milestone reflects Polyrizon’s
continued progress toward advancing its intranasal technology platform and bringing novel preventive solutions for respiratory conditions
closer to patients.
About Polyrizon
Polyrizon is a development stage biotech company
specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based
shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial
tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring
building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield
containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the
bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional
technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients,
or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as
“expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example,
the Company is using forward-looking statements when it discusses continuing to advance its naloxone program as part of its broader intranasal
platform strategy. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs
and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in
good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual
results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are
subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s
reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks
detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking
statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to
reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking
information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements,
no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not
incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
